1	Title: Clinical and economic inpatient burden of respiratory syncytia
2	virus (RSV) infections in children < 2 years of age in Germany, 2014-
3	2019: a retrospective health claims analysis
4	Authors in order:
5	Caroline Lade <sup>1</sup> – Lead and corresponding author
6	Lea Bayer <sup>1</sup>
7	Bennet Huebbe <sup>2</sup>
8	Jennifer Riedel <sup>3</sup>
9	Sima Melnik <sup>3</sup>
10	Gordon Brestrich <sup>1</sup>
11	Christof von Eiff <sup>1</sup>
12	Tobias Tenenbaum⁴
13	
14	Affiliations:
15	<sup>1</sup> Pfizer Pharma GmbH, Berlin, Germany
16	<sup>2</sup> IGES Institut, Berlin, Germany

<sup>3</sup> Gesundheitsforen Leipzig GmbH, Leipzig, Germany

18	<sup>4</sup> Sana Klinikum Lichtenberg, Clinic for Child and Adolescent Medicine, Academic Teaching Hospital
19	Charité-Universitätsmedizin Berlin, Germany
20	
21	Conflict of Interest Statements:
22	CL, LB, GB and CvE are all employees of Pfizer Pharma GmbH in Germany, the sponsor of this study. SM
23	and JR are employees of Gesundheitsforen Leipzig GmbH, paid by Pfizer to conduct the study. BH is a
24	former employee of Pfizer Pharma GmbH Germany. TT is an expert in the field of RSV and received an
25	honorarium from Pfizer for input on the study design and review of the results.
26	Funding:
27	This study was sponsored by Pfizer.
28	
29	

# **ABSTRACT**

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Background: Respiratory syntactical virus (RSV) is a common cause for severe lower respiratory tract infections (LRTI) in children <2 years of age in Germany – though little is known about the clinical and economic burden of RSV in children with and without risk factors per month of life. Methods: In a retrospective health claims analysis, we identified RSV inpatient cases between 2014 and 2019. We assessed incidence rates, mortality rate, health resource utilization, associated direct costs per case and excess costs for 30, 90 and 365 days after hospital admission matched to a control group. The outcomes are reported separately for the first and second year of life (i.e., for infants and toddlers) and were stratified by month of life, preterm and risk status (i.e., presence of underlying disease: chronic respiratory or cardiac disease, immunosuppression, neurological diseases, diabetes, conditions originating in the perinatal period). Results RSV-attributable hospital incidence rate was higher in infants (30.25/1,000) than toddlers (14.52/1,000), highest in the first three months of life (44.21/1,000), in infants born preterm (64.76/1,000) or with any underlying disease (54.85/1,000). Mortality rate was also higher for infants (0.08/1,000) than toddlers (0.04/1,000). Mean 30-day excess costs ranged from 2,953 € for infants born full-term at no risk, hospitalized for 5 days, to 6,694 € for infants born extremely premature, hospitalized for 7 days. Conclusion: In Germany, the clinical and economic burden of RSV is substantial, especially in the most vulnerable population, that is, very young infants, those born premature and/or those with an underlying disease.

#### Introduction

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infections (LRTI) at all ages worldwide. RSV infections are most severe, often leading to hospitalizations, in children under the age of 5 [1]. In children, RSV manifests with symptoms ranging from rhinitis, bronchiolitis to pneumonia [2]. By the age of two years, most children have had an RSV infection at least once [3]. Severe cases occur especially in high-risk groups which include children born prematurely and children with underlying diseases like chronic respiratory or cardiac disease, immunosuppression, neurological diseases, diabetes, or conditions originating in the perinatal period [4]. Morbidity and mortality due to RSV are higher in children at risk than no risk [5]. However, little is known about either clinical or economic burden of RSV in the most vulnerable children < 2 years of age in Germany. The global burden of RSV was estimated in 2019 at 33 million episodes a year among children under five years of age or younger, with 3.6 million hospitalizations, 26,300 RSV in-hospital deaths, and 101,400 RSVattributable overall deaths [6]. The majority of cases were accounted for by children under one year of age. For industrialized countries, hospital incidence rates were reported for RSV-associated acute LRTI at 38.5/1,000 in children under one year of age and 24.3/1,000 in children younger than 5 years of age [6]. Hospital incidence rates are highest within the first month of age, decreasing steadily month by month thereafter [7, 8]. In Germany, the clinical burden of RSV in children < 2 years of age has only very recently been described [9-11] but data on the burden of RSV in more vulnerable children are still missing, that is for very young infants, children born prematurely or with an underlying disease. Hospital incidence rates of 14.9-28.6 per 1,000 infants (i.e., first year of life) were reported between 2019-2022 [11]. For toddlers (i.e., second year of life), the hospital incidence rate ranged between 2.5-5.6 per 1,000 persons. Thereby, most RSV hospital cases were identified in infants under six months of life based on medical records of children under five years of age between 2015 and 2018 [10] – but no incidence rates were reported. Despite high awareness

and good testing practice, incidence rates in children may be underestimated [12]. Likely large proportions of cases of respiratory diseases that are not readily identified as RSV may be documented as RSVattributable unspecified diagnoses of, for instance, unspecified bronchiolitis, in young children under the age of 2 years [13], contribute to an underreporting of RSV. Such underestimation in combination with an ever-increasing RSV hospital incidence rate that almost doubled since 2010 [9] highlights the importance to better understand the clinical burden of RSV in more detail, especially in the most vulnerable population of children in Germany. In addition to the clinical burden, RSV infections also pose a substantial economic burden to the healthcare system. A recent review summarizing data from Europe, North America, and Australia between 1987 and 2017 reported average costs of 3,452 € per inpatient episode among children under five years of age [14]. Specifically for Germany, costs of 3,001 € - 3,961 € were reported for RSV cases in children ≤2 years of age between 2019-2022 [11]. For children under one year of age, costs of 3,329 € were reported between 2015-2018 [9]. Costs increased to 7,825 € - 11,045 € for severe cases that required ICU admission [11]. Since previous reports of costs in 2002, costs have increased by approximately 15% [15]. With the highest clinical burden in infants with risk factors, more detailed data are needed on healthcare resource utilization (HRU) and associated costs of RSV in the most vulnerable population to better understand the economic burden in Germany. To fill in these gaps in the clinical and economic burden of RSV in children in Germany, we conducted retrospective analyses using health claims data to assess the incidence rate, mortality, HRU, and costs associated with RSV in hospitalized children <2 years of age in Germany from 2014 to 2019, stratified by month of life and the presence of risk factors (prematurity and/or underlying disease).

# Methods

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

#### Study design and data source

In this study, we conducted an observational, retrospective database analysis. Anonymized health claims data were obtained from the German Analysis Database for Evaluation and Health Services Research [Deutsche Analysedatenbank für Evaluation und Versorgungsforschung] (DADB) administered by Gesundheitsforen Leipzig GmbH [16] containing Statutory Health Insurance (SHI) data on approximately four million insured persons (~5 % of the SHI population), representative of the German population in terms of age, sex and morbidity.

# Study population and case identification

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Health claims data were selected from insured children ≤ 24 months of life, born between January 1<sup>st</sup>, 2013, and December 31st, 2019, who were fully observable for either their first or second year of life or until death. Cases were identified within an observation period between January 1st, 2014 and December 31st, 2019, to avoid confounds due to irregular RSV seasons during and after the COVID-19 pandemic [17]. Case identification was based on either a narrow definition including RSV-specific ICD-10-GM codes, J12.1 (acute pneumonia due to RSV), J20.5 (acute bronchitis due to RSV), J21.0 (acute bronchiolitis due to RSV), and B97.4 (RSV classified elsewhere) or a wide definition including both RSV-specific diagnosis codes and RSV-attributable ICD-10-GM codes of unspecified bronchiolitis (J21.8, J21.9), bronchitis (J20.8, J20.9), pneumonia (J12.8, J12.9, J18.8, J18.9) or acute lower respiratory tract infections (J22, UBP). In this wide definition, UBP cases were included if the diagnosis occurred during the RSV season as defined by RKI for each year, typically between December and February according to Cai et al. [18] (see Supplemental Table 1). Previous studies have repeatedly employed such wide case definition [e.g., 19, 20] to increase the sensitivity of capturing RSV cases without a substantial loss of specificity [21]. For case identification, main and secondary diagnoses were taken into account. All analyses were carried out separately for incident infants (first year of life) and toddlers (second year of life; for case characteristics, see Table 1). The age of patients in months of life was estimated at the time

of the index diagnosis. For the analysis of costs, first, patients with multiple cases (n = 824 cases, 10.7 %), second, patients who were not fully observable for the maximum follow-up period of one year after the index date (n = 208 cases, 3%), third, patients for who there was no exact match amongst control patients (n = 25, 0.38 %) were excluded in order to reliably and consistently assess long-term costs (Figure S1). Patients were further characterized by preterm status (full-term, extreme preterm and early/late preterm) and risk status (no risk, any risk, Table 1). Preterm status was defined by the presence of the ICD-10 codes P07.2, which characterizes newborns with extreme prematurity, born before the 29<sup>th</sup> gestational week (henceforth extreme preterm), and P07.3 which characterizes other preterm infants, infants born between the 29<sup>th</sup> and the 37<sup>th</sup> gestational week (henceforth early/late preterm). Risk status was defined by the presence of at least one risk factor based on ICD-10 codes for conditions originating in the perinatal period, chronic or congenital cardiac or respiratory disease, immunosuppression, neurological disease, diabetes mellitus or a patient history of prophylactic immunotherapy (Table S2). As conditions originating in the perinatal period also include prematurity, the clinical burden of RSV was additionally described for children at risk excluding prematurity, that is for children with underlying disease born full-term.

# Definition of episodes.

Hospital episodes were defined as overnight stays. The start of an episode was defined by the admission date of either main or secondary RSV or UBP diagnosis (i.e., index date). An episode lasted until the discharge date or until no further RSV or UBP diagnosis occurred within 30 days of the previous diagnosis to capture possible readmissions [10] and to avoid an overestimation of case counts. Two types of episodes were classified: first, RSV episodes which were based on either RSV-specific diagnosis codes only or RSV-specific diagnosis codes plus an additional UBP diagnosis code during the duration of the episode; second, UBP episodes that are based on UBP diagnosis codes only. For the wide case definition, both RSV

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

and UBP episodes were considered for the assessment of outcomes measures; for the narrow definition only RSV episodes were considered. Assessment Study outcome measures included incidence rates, 90-day all-cause mortality rate, all-cause healthcare costs and HRU. Incidence rates were calculated as number of cases divided by the annual number of newborns in the DADB (Table S6) and are expressed per 1,000 persons per year. For the estimation of incidence rates per month of life, the annual base population was divided by 12 months. For age group stratifications, the annual base population was divided by 12 and then multiplied by the number of months the respective age group encompasses, assuming approximately equal numbers of children per month of life. The 90-day all-cause mortality rate was calculated as the number of deceased patients within the episode plus 90 days thereafter divided by the total population size across the observation period. Due to relatively low numbers of fatal cases, mortality rates could only be computed across the entire study period from 2014-2019. The mortality rate was stratified by preterm and risk status. HRU assessment included hospital length of stay (LOS), ICU admission status and ventilation use. LOS was assessed per episode and stratified by <5, 5-8 and >8 days. In addition, LOS was assessed for all-cause hospitalizations during 30, 90 and 365 days after the index date. ICU stay was assessed per episode based on admission to or discharge from ICU. Ventilation use was assessed per episode based on OPS codes for oxygen therapy (OPS 8-720), non-invasive ventilatory support (High Flow Nasal Cannula, HFNC: OPS 8-711.4, OPS 8-712.1; Continuous Positive Airway Pressure, CPAP: OPS 8-711.0, OPS 8-712.0), invasive mechanical ventilation (OPS 8-711.1, OPS 8-711.2). Mean direct healthcare costs were calculated per episode, mean excess costs were estimated for short-

and longer-term follow-up time windows (30, 90, 365 days after hospital admission). Excess costs were

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

compared 1:1 to matched control patients across healthcare sectors based on month of life, sex, preterm status using Mann-Whitney-Wilcoxon test for continuous variables. P-values were adjusted for multiple comparisons, if necessary, using the Benjamini-Hochberg procedure to limit the probability of false detections. The control cohort was also observable for at least one year after the index date of the matched incident patient and did not have an RSV diagnosis within that time or a UBP diagnosis during the RSV season. 25 cases (0.4%) for which there was no exact match were excluded from all cost analyses. All cost values were adjusted to 2019 per consumer price index [22] per case per time window before being averaged for each time window across the study period 2014-2019. All outcomes were stratified, whenever case numbers allowed, by episode type (RSV-UBP, RSV, UBP), month of life (1-12 months and 13-24 months), calendar month (January to December), preterm (fullterm, extreme preterm and early/late preterm) and risk status (no risk, any risk). All analyses were descriptive and exploratory. As there were no a priori hypotheses, no planned comparisons were performed. Finally, we extrapolated mean costs to the population-level in order to estimate the average annual economic burden for Germany. To this end, we first determined an extrapolation factor per calendar year based on the number of live births per year (mean across 2014 - 2019 = 765,680 live births; [23]) and the number of newborns in the DADB (both in Table S6) and then multiplied that with the annual case numbers. The extrapolated mean annual number of hospitalizations were multiplied with the mean excess costs for 30 days after hospital admission. Ethical considerations. This study used aggregated and anonymized health claims data, therefore not requiring approval from Institutional Review Boards or Ethical Committees or informed consents from patients. The study was conducted in accordance with legal and regulatory requirements and research practices described in the "Good Epidemiological Practice guidelines issued by the International Epidemiological Association" [24].

Results

Between 2014-2019, there were 183,952 infants within their first year of life and 146,752 toddlers in their second year of life in the database (for more information on the annual base population, see Table S6).

### <u>Clinical burden – incidence and mortality</u>

We identified 5,565 cases in infants (based on 5,248 main diagnoses, 317 secondary diagnoses) and 2,131 cases in toddlers (based on 1,927 main diagnoses and 204 secondary diagnoses) across the study period (for further characteristics see Table 1; also see patient flow in Figure S1). Most cases were identified within the RSV season between December and March (88% of the cases in infants, 93% in toddlers). Among infants, 66.6% of cases were identified based on an RSV diagnosis code; in toddlers it was 34.8%. In infants, 45.65% cases were diagnosed with acute bronchiolitis due to RSV, 29.86% with acute bronchitis due to RSV, 21.70% with acute pneumonia due to RSV and 2.79% with RSV classified elsewhere. In contrast, in toddlers, 43.10% cases were diagnosed with acute pneumonia due to RSV, 32.90% with acute bronchitis due to RSV, 18.97% with acute bronchiolitis due to RSV and 5.03% with RSV classified elsewhere. Moreover, 86.70% of infants were born full-term, 13.30% preterm, similar in toddlers. 30.8% of infants and 35.1% of toddlers were considered at risk (see Table 1 for more specific case characteristics).

The hospitalization incidence rate in infants was estimated at 28.95-33.07 per 1000 between 2014 and 2019, with a mean of 30.25 per 1,000 (Table 2). In toddlers, the incidence rate was estimated at 10.95-18.13 per 1,000 between 2015 and 2019, with a mean of 14.52 per 1,000 (for toddlers we only included data from 2015 onwards to fully observe all children in the database within their second year of life who were born between 2013-2019. More specifically, for infant cases based on an RSV-specific diagnosis, the annual hospitalization incidence rate was 17.25-22.89 per 1,000 between 2014-2019 with a mean of 20.15 per 1,000; for toddlers, it was 3.70-6.58 per 1,000 with a mean of 5.05 per 1,000. Extrapolated to the

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

population-level, that is 23,152 cases of infants (15,469 RSV-specific cases) and 11,228 cases of toddlers (3,907 RSV-specific cases) per year. Across the first two years of life, 50% of cases occur already within the first 6 months of life, with specifically high incidence rates in the second and third month of life (57.28 and 44.88 per 1000 personyears, respectively), continuously decreasing thereafter, across the second year of life (Figure 1, Table S4). This is driven by infants with an RSV-specific diagnosis for which the incidence rate in the second and third month was at 45.21 and 34.84, respectively. For infants with an RSV-specific diagnosis, the incidence rate is 2.4 times higher in the first three months than for the remaining first year of life, and 2.9 times higher in the first 6 months than in the second half a year of life. Incidence rates were highest for infants born prematurely (preterm: 64.76, full-term: 27.97) and for infants at risk including prematurity (any risk: 58.73, no risk: 28.92; for more details see Table 3), especially shortly after birth (Figure 1, Table S4). Compared to infants at no risk, incidence rates were 2.2 times higher in infants with any underlying disease, 2.5 times higher in early/late preterms, and 3.3 times higher in infants born extremely premature. For toddlers, prematurity and underlying risk factors remain to play a great role with highest incidence rates in toddlers that were born prematurely (preterm: 34.49, fullterm: 13.19) and those at risk (at risk: 28.92, no risk: 11.44). Compared to toddlers at no risk, incidence rates were 2.3 times higher in toddlers with any underlying disease, 2.8 times higher in toddlers with early/late prematurity, and 6.1 times higher in toddlers with extreme prematurity. Between 2014-2019, 20 children died within the episode or 90 days thereafter – 14 infants and 6 toddlers. 9 of the fatal cases were born prematurely, 11 full-term. All 20 fatal cases had at least one risk factor (including prematurity). 11 children died after an RSV-specific diagnosis, 9 after a UBP diagnosis (that occurred within the RSV season). Extrapolated to the population-level, there were a total of 538 fatal cases per year, 350 infants and 188 toddlers. The annual all-cause mortality rate after an RSV infection in

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

children under two years is estimated at 0.06 per 1,000 children, 0.08 per 1,000 infants and 0.04 per 1,000 toddlers. Economic burden and healthcare resource utilization related to RSV infections. Mean direct and mean excess costs as well as HRU were estimated based on 4,909 cases in infants and 1,730 cases in toddlers across the study period for which there was a 1:1 exact matched control patient and which were observable for at least one year after the index date (for further characteristics see Table 1; also see patient flow in Figure S1). Among infants, 68.7% of cases were identified based on an RSVspecific diagnosis code, in toddlers it was 35.7%. Infants were hospitalized for a median LOS of 5 days, toddlers for 4 days, within 30 days after hospital admission. The LOS for both infants and toddlers with an RSV-specific diagnosis was 5 days. Infants and toddlers with acute pneumonia due to RSV (J12.1) had the longest median LOS of 7 and 6 days, respectively. Children with acute bronchiolitis due to RSV (J21.0) had shorter median LOS of 5 days; children with acute bronchitis due to RSV (J20.5) or RSV classified elsewhere (B97.4) had the shortest median LOS of 4 days. For infants born early/late preterm, the median LOS was 6 days. For those born extreme premature, it was 7 days or even 8 days for infant cases with an RSV-specific diagnosis. In toddlers, this was 5 days for those born early/late preterm and 6 days for those with extreme prematurity. 0.9% of cases in infants were admitted to ICU, whereby 83.7% infants were born full-term and 60.5% were between the age of 1-3 months of life. For toddlers, 0.7% of cases were admitted to ICU, whereby 91.7% were born full-term and 66.7% were between 13-18 months of life. Risk factors (including prematurity) did not increase the likelihood of ICU admission (55.8% infants, 44.7% toddlers were admitted to ICU). Further, 5.9% of infants required some form of ventilation use: 1.8% oxygen therapy, 3.6% other non-invasive ventilatory support (1.9% HFNC, 1.7% CPAP) and 0.5% invasive mechanical ventilation. Only 1% of toddlers required ventilatory support (0.9% HFNC, 0.1% CPAP).

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

Mean direct costs attributed to those healthcare resource utilizations were higher in infants (3,775 €) than in toddlers (3,062 €, for more details per age group see Table 4), higher for those born premature or at risk compared to children at no risk (Table 5). For infants, mean costs were 4.7 times higher for cases that required ICU admission (17,273 €) than for cases which did not require ICU admission (3,655 €). For toddlers, mean costs were even 9.5 times higher for cases that required ICU admission (27,605 €) than for cases which did not require ICU admission (2,891 €). Infant cases that required invasive mechanical ventilation support were especially high, with mean costs up to 75,188 €. For both infants and toddlers, mean costs were higher for cases with an RSV episode (4,021 € and 3,641 €, respectively) than for cases with a UBP episode (3,234 € and 2,741 €, respectively). Thereby, mean costs varied between different RSV-specific diagnosis codes. That is, in infants, in the order from high to low case numbers, on average, acute bronchiolitis due to RSV (J21.0) cost 4,061€; acute bronchitis due to RSV (J20.5) cost 2,883 €; acute pneumonia due to RSV (J12.1) cost 5,773 €; cases with RSV classified elsewhere (B97.4) cost 4,996 €. In toddlers, acute pneumonia due to RSV (J12.1) cost 4,458 €; acute bronchitis due to RSV (J20.5) cost 3,118 €; acute bronchiolitis due to RSV (J21.0) cost 3,310 €; cases with RSV classified elsewhere (B97.4) cost 3,706 €. Mean excess costs increased for both infants and toddlers over the follow-up periods of 30, 90 and 365 days (Table 4), whereby costs were consistently higher for patients than matched controls (Table S5). Moreover, mean excess costs were higher for children born premature or at risk (Table 5). Mean excess costs within 30 days after hospital admission were also higher for both infants and toddlers that required ICU admission during the RVS/UBP episode (11,809 € and 23,556 €), respectively) than for infants and toddlers that did not require ICU admission (3,318 € and 2,924 €, respectively). Additionally, mean excess costs within 30 days after hospital admission were higher for cases that required ventilatory support during the RVS/UBP episode, ranging from 5,808 € for oxygen therapy to 31,404 € for invasive mechanical

ventilation in infants. For both infants and toddlers, cases based on an RSV episode were more costly (3,669 € and 3,521 €, respectively) than cases based on a UBP episode (2,786 € and 2,815 €, respectively).

An estimation of the annual economic burden of RSV-related hospitalizations, based on annual case numbers extrapolated to the population-level of 23,152 infants and 11,228 toddlers at mean excess costs of 3,392 € for infants and 3,067 € for toddlers, results in costs of 112,967,860 € per year for children under the age of 2 years; that is, ~64.5 mil € for cases with an RSV-specific diagnosis (based on 15,469 cases in infants and 3,907 cases in toddlers) and ~48.5 mil € for cases with a UBP diagnosis (based on 7,683 cases in infants and 7,321 cases in toddlers).

#### Discussion

In this retrospective cohort study based on a representative sample of SHI data, we assessed a nation-wide, and population-based clinical and economic burden of RSV infections in young children < 2 years in Germany between 2014-2019, quantifying hospital incidence rate, mortality rate, HRU and associated costs of RSV. The results how that hospital incidence rate, HRU and associated costs were higher in infants than in toddlers and were highest for very young infants, infants born prematurely and infants at risk.

The results show that hospital incidence rates from 2014-2019 that were based on a wide case definition, taking RSV-UBP cases into account, (28.95-33.07 per 1,000 in infants; 10.95-18.13 per 1,000 in toddlers) are higher than previous reports for Germany from 2019-2022 that were based on a narrow case definition, considering RSV-specific cases only (14.9-28.6 per 1,000 in infants, 2.5-5.6 per 1,000 in toddlers; [11]). Though, our hospital incidence rates based on the narrow case definition are lower (18.50-23.74 per 1,000 in infants; 3.98-6.95 per 1,000 in toddlers) – likely due to the earlier observation period; the disease burden is known to increase year by year [9]. Applying an underreporting factor of 1.35 (1.3 in infants < 6 months and 1.4 in infants 6-11 months of age) as reported by Haeberer et al. [12] to our RSV-specific incidence rate results in 24.98-32.05 per 1,000 in infants which approximates estimates for

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

the overall RSV-UBP study population. While these estimates are lower than the mean hospital incidence rate of 38.5/1,000 in infants in other industrialized countries across the world [6], they are comparable to estimates from neighboring European countries, for instance Denmark with a hospital incidence rate of 29/1,000 in infants [8]. This substantiates an estimation based on a wide case definition including RSV-UBP cases to describe the RSV-attributable clinical burden for infants and toddlers. We also show that hospital incidence rates were highest in very young infants during the first months of life, in line with previous reports [7, 8, 25, 26]. For Germany, between 2006-2018, Johannesen et al. [26] reported substantially higher RSV-attributable hospital incidence rates of 72.5 per 1,000 in infants between 1-3 months of life than 38.6 and 17.5 per 1,000 in infants between 4-6 and 7-12 months of life, respectively. In comparison, we reported slightly lower incidence rates of 44.21, 35.36 and 20.72 per 1,000 persons in infants between 1-3, 4-6 and 7-12 months of life, respectively. However, this is likely due to the difference in methodology; while we are using counts of ICD-10 diagnosis codes, Johannesen et al. [26] modelled incidence rates using time-series estimation. The modelled estimates are comparable to average incidence rates reported across the European Union (EU): 71.5, 38.9 and 17.6 per 1,000 persons in infants between 1-3, 4-6 and 7-12 months of life, respectively [27]. As time-series modeling is less sensitive to the effects of underreporting and as the results are comparable across the EU, the burden of RSV in children may be even higher in Germany than the results of our study suggest – despite the inclusion of UBP cases during the RSV season to take underreporting into account. Future studies employing novel approaches to the estimation of incidence rates like time-series modeling are needed. Further extending previous findings, we show in this study that the risk of contracting severe forms of RSV in newborns is approximately twice as high right after birth in infants at risk, that is infants born prematurely or with any underlying disease, compared to infants without any risk factors. Several risk factors like prematurity, bronchopulmonary dysplasia (BPD) or congenital heart disease (CHD) have been widely acknowledged as risk factors for severe outcomes of RSV, globally [28-31] and in Germany

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

[4], but no detailed evidence is yet available on the burden of RSV in this most vulnerable population during the first few months of life in Germany. For infants with underlying disease (including BPD and CHD), we show that the risk of infection is already imminent right after birth, in the first month of life. For preterm infants, the risk is highest during the second and third month of life. As newborns have an immature immune system, and their small airways are especially affected by swelling and mucous production due to the infection and inflammation [32]), in the first few months of life infants are most vulnerable, especially when at risk (due to prematurity or any underlying disease). The results of this study show that the impact of premature birth and underlying disease on the risk for hospitalization seems to persist well beyond the first few months of life, well into toddler age and possibly beyond. Moreover, while the hospital burden of RSV in Germany is already substantial, it represents only part of the overall burden of RSV, including largely severe cases that require hospitalization. The overall burden of RSV, however, includes also less severe RSV infections that present to the outpatient sector. The estimation of the outpatient burden is, however, challenging not least because of similar symptomology to other respiratory diseases and less established testing practice, leading to an even larger underreporting. Data on the outpatient burden are currently missing and should be assessed in the future once more advances are made to identify RSV in the outpatient sector. HRU and associated costs underline the risk for severe outcomes of RSV in children with risk factors as seen in longer LOS and admissions to ICU. We show that for children born early/late or extreme preterm, the LOS is one and two days higher, respectively, than the previously reported 5 days [9-11], 2.1%-8.0% infants were reported to be admitted to ICU [9-11] – largely exceeding our estimates of ~1%, likely due to methodological differences to identify ICU admissions. The highest ICU admission rate, though, was previously found in children under 6 months of age (9.3%) [10]. Associated costs were highest in the first few months of life, especially for those at risk. This extends previous findings for Germany [9, 11] and is in line with other recent cost estimates from other European

countries like France [25, 33]. For example, Kramer et al. [33] estimated mean costs per inpatient episode for full-term infants at 3,437 €, with higher costs for infants <3 months of age (3,958 €) than infants >3 months of age (3,234 €). Kramer et al. [33] also reported higher estimates in infants born prematurely at 6,324 €. For Germany, we additionally show that costs are specifically high for infants born extremely prematurely. However, even though the costs are highest for children at risk, the economic burden is driven by the large clinical burden in otherwise healthy children under the age of two years.

Both clinical and associated economic burden may be reduced in effect of a new RSV intervention program. At this point in time, three preventive measures have been granted market authorization for the prevention of RSV-LRTI in infants. One monoclonal antibody (mAB), Palivizumab [34, 35], has been used to prevent severe RSV infections in children at risk since the 1990s and is now being complemented by a recently approved mAB with a longer half-life (Nirsevimab, [36-38]). The latter has just been recommended for all infants regardless of their risk status in Germany [39]. While mAbs can protect from the time of administration, the recently approved maternal vaccine (RSVpreF, [40, 41]) provides protection immediately from birth, as children are born with protective antibodies that were transferred by the vaccinated mother during pregnancy.

# **Limitations and Implications**

Using health claims data to analyze clinical and economic burden has numerous strengths, but also several limitations. First, it is not possible to determine whether an RSV-specific laboratory detection assay was positive prior to ICD-10 coding, as virological confirmation is not a requirement, and the results of tests are not available in health claims data. However, RSV-codes (J12.1, J20.5, and J21.0) are usually allocated after laboratory-confirmed RSV infection in the hospital setting [9]. Second, while the database used in this study is representative of the population, available SHI databases typically include only ~5% of the population, capturing many but likely not all cases in contrast to public databases. However, SHI databases

have the advantage of more detailed information on patient characteristics like preterm or risk status which was crucial in this study to assess the burden in the most vulnerable population. Though the number of patients with such specific characteristics are low. This affects specifically results on mean costs which are most robust if the sample was large. However, to date this is the best estimation available. That is also the case for the estimation of excess costs; the best possible procedure for matching patients of such young age by at least month of life, sex and preterm status to controls was only feasible across healthcare sectors. As a result only 12% of controls included in the analysis had a hospitalization within 365 days after the index date of the matched incident patient. This was, however, the best matching procedure possible. Moreover, we employed an approach – the inclusion of UBP cases during the RSV season – that previous studies have already used in order to take underreporting due to misdiagnosis into account [e.g., 19, 20]. While overestimation may be a concern to this approach, the number of cases that are added correspond approximately to the underreporting factor that has previously been suggested for that age group [12]. Also, novel approaches like time-series modeling report even higher incidence rates compared to the standard estimation employed here [26]. However, for comparability to previous studies [9, 11], we also report estimates on a narrow case definition based on RSV-specific diagnosis codes only.

# Conclusion

This large-scale observational study is the first to provide detailed nation-wide, population-based epidemiological and economic estimates of the RSV-attributable hospital burden by months of life, preterm and risk status in Germany. The results show a substantial burden among the youngest children with RSV infections, right after birth. Although the highest risk of severe RSV was found in children born prematurely or with an underlying disease, most children who needed to be hospitalized were not at risk – emphasizing the need for broad protection already at birth.

- Acknowledgements: Medical writing support was provided by Qi Yan, PhD, MS (Pfizer, Inc). We thank
- 397 Julia Schiffner-Rohe for valuable discussions throughout the study process.

#### References:

- 400 1. Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge from infancy to old age.
- 401 Thorax. 2019;74(10):986-93. <a href="https://doi.org/10.1136/thoraxjnl-2018-212212">https://doi.org/10.1136/thoraxjnl-2018-212212</a>.
- 402 2. Jha A, Jarvis H, Fraser C, Openshaw PJM. Respiratory Syncytial Virus. In: Hui DS, Rossi GA, Johnston SL,
- 403 editors. SARS, MERS and other Viral Lung Infections. Sheffield (UK): European Respiratory Society; 2016.
- 404 3. Barr R, Green CA, Sande CJ, Drysdale SB. Respiratory syncytial virus: diagnosis, prevention and
- 405 management. Ther Adv Infect Dis. 2019;6:2049936119865798.
- 406 https://doi.org/10.1177/2049936119865798.
- 407 4. Cai W, Buda S, Schuler E, Hirve S, Zhang W, Haas W. Risk factors for hospitalized respiratory syncytial
- 408 virus disease and its severe outcomes. Influenza Other Respir Viruses. 2020;14(6):658-70.
- 409 https://doi.org/10.1111/irv.12729.
- 410 5. Sommer C, Resch B, Simões EA. Risk factors for severe respiratory syncytial virus lower respiratory tract
- 411 infection. Open J Med Microbiol. 2011;5:144-54. https://doi.org/10.2174/1874285801105010144.
- 412 6. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease
- 413 burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children
- 414 younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-64.
- 415 https://doi.org/10.1016/s0140-6736(22)00478-0.
- 416 7. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al. Respiratory syncytial virus-
- associated hospitalizations among children less than 24 months of age. Am Acad Pediatr.
- 418 2013;132(2):341-8. https://doi.org/10.1542/peds.2013-0303.
- 419 8. Jepsen MT, Trebbien R, Emborg HD, Krause TG, Schønning K, Voldstedlund M, et al. Incidence and
- seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015.
- 421 Euro Surveill. 2018;23(3):17-163. https://doi.org/10.2807/1560-7917.Es.2018.23.3.17-00163.

422 9. Niekler P, Goettler D, Liese JG, Streng A. Hospitalizations due to respiratory syncytial virus (RSV) 423 infections in Germany: a nationwide clinical and direct cost data analysis (2010-2019). Infection. 2023. 424 https://doi.org/10.1007/s15010-023-02122-8. 425 10. Hartmann K, Liese JG, Kemmling D, Prifert C, Weißbrich B, Thilakarathne P, et al. Clinical Burden of 426 Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years (INSPIRE Study). J Infect Dis. 427 2022;226(3):386-95. https://doi.org/10.1093/infdis/jiac137. 428 11. Wick M, Poshtiban A, Kramer R, Bangert M, Lange M, Wetzke M, et al. Inpatient burden of respiratory 429 syncytial virus in children ≤2 years of age in Germany: A retrospective analysis of nationwide 430 hospitalization data, 2019-2022. Influenza Other Respir Viruses. 2023;17(11):e13211. 431 https://doi.org/https://10.1111/irv.13211. 432 12. Haeberer M, Bruyndonckx R, Polkowska-Kramek A, Torres A, Liang C, Nuttens C, et al. Estimated 433 Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 434 2016-2019. Infect Dis Ther. 2024;13(3):463-80. https://doi.org/10.1007/s40121-024-00920-7. 435 13. Hasegawa K, Goto T, Hirayama A, Laham FR, Mansbach JM, Piedra PA, et al. Respiratory Virus 436 Epidemiology Among US Infants With Severe Bronchiolitis: Analysis of 2 Multicenter, Multiyear Cohort Studies. Pediatr Infect Dis J. 2019;38(8):e180-e3. https://doi.org/10.1097/inf.000000000002279. 437 438 14. Zhang S, Akmar LZ, Bailey F, Rath BA, Alchikh M, Schweiger B, et al. Cost of Respiratory Syncytial Virus-439 Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global 440 Level: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222(Suppl 7):680-7. 441 https://doi.org/10.1093/infdis/jiz683.

21

community-acquired and nosocomial lower respiratory tract infections in young children in Germany.

European journal of pediatrics. 2005;164(10):607-15. https://doi.org/10.1007/s00431-005-1705-0.

442 15. Ehlken B, Ihorst G, Lippert B, Rohwedder A, Petersen G, Schumacher M, et al. Economic impact of

443

- 445 16. Gesundheitsforen Leipzig GmbH. German Analysis Database for Evaluation and Health Service Research
- [Deutsche Analysedatenbank für Evaluation und Versorgungsforschung]. (2024).
- 447 <a href="https://www.gesundheitsforen.net/GFL/Services/Analytik/Gesundheitsforen%20Leipzig">https://www.gesundheitsforen.net/GFL/Services/Analytik/Gesundheitsforen%20Leipzig</a> DADB Q1%202
- 448 024.pdf. Accessed 2024.
- 449 17. Kiefer A, Pemmerl S, Kabesch M, Ambrosch A. Comparative analysis of RSV-related hospitalisations in
- 450 children and adults over a 7 year-period before, during and after the COVID-19 pandemic. J Clin Virol.
- 451 2023;166:1386-6532. https://doi.org/https://doi.org/10.1016/j.jcv.2023.105530.
- 452 18. Cai W, Dürrwald R, Biere B, Schweiger B, Haas W, Wolff T, et al. Determination of respiratory syncytial
- virus epidemic seasons by using 95% confidence interval of positivity rates, 2011-2021, Germany.
- 454 Influenza Other Respir Viruses. 2022;16(5):854-7. https://doi.org/10.1111/irv.12996.
- 455 19. Bandeira T, Carmo M, Lopes H, Gomes C, Martins M, Guzman C, et al. Burden and severity of children's
- 456 hospitalizations by respiratory syncytial virus in Portugal, 2015-2018. Influenza Other Respir Viruses.
- 457 2023;17(1):e13066. <a href="https://doi.org/https://10.1111/irv.13066">https://doi.org/https://10.1111/irv.13066</a>.
- 458 20. Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and
- economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis.
- 460 2022;22(1):759. https://doi.org/https://10.1186/s12879-022-07745-0.
- 461 21. Hamilton MA, Calzavara A, Emerson SD, Djebli M, Sundaram ME, Chan AK, et al. Validating International
- 462 Classification of Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus
- 463 hospitalizations. PLoS One. 2021;16(1):1-12. https://doi.org/10.1371/journal.pone.0244746.
- 464 22. Destatis Statistisches Bundesamt. 61111-0001 Verbraucherpreisindex: Deutschland in Jahre. (2023).
- 465 https://www-genesis.destatis.de/genesis//online?operation=table&code=61111-
- 466 0001&bypass=true&levelindex=0&levelid=1724158016992#abreadcrumb. Accessed 2024.

- 467 23. Destatis Statistisches Bundesamt. Geburten Veränderung der Zahl der Lebendgeborenen zum
- jeweiligen Vorjahr. (2024). <a href="https://www.destatis.de/DE/Themen/Gesellschaft-">https://www.destatis.de/DE/Themen/Gesellschaft-</a>
- 469 <u>Umwelt/Bevoelkerung/Geburten/Tabellen/lebendgeborene-differenz.html</u>. Accessed 2024.
- 470 24. The International Epidemiological Association. Good Epidemiological Practice. Guidelines for Proper
- 471 Conduct of Epidemiological Research. (2007). https://ieaweb.org/. Accessed 2024.
- 472 25. Demont C, Petrica N, Bardoulat I, Duret S, Watier L, Chosidow A, et al. Economic and disease burden of
- 473 RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis.
- 474 2021;21(1):730. https://doi.org/10.1186/s12879-021-06399-8.
- 475 26. Johannesen CK, van Wijhe M, Tong S, Fernández LV, Heikkinen T, van Boven M, et al. Age-Specific
- 476 Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time
- 477 Series Analysis. J Infect Dis. 2022;226(Suppl 1):29-37. https://doi.org/10.1093/infdis/jiac150.
- 478 27. Del Riccio M, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, Fernandez LV, Teirlinck AC, et al.
- 479 Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated
- 480 hospitalizations in children under 5 years. J Infect Dis. 2023;228(11):1528-38.
- 481 https://doi.org/10.1093/infdis/jiad188.
- 482 28. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory
- syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-98.
- 484 https://doi.org/10.1056/NEJMoa0804877.
- 485 29. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV)
- 486 infection. J Pediatr. 2003;143(5 Suppl):112-7. https://doi.org/10.1067/s0022-3476(03)00508-0.
- 487 30. Shi T, Vennard S, Mahdy S, Nair H, investigators R. Risk Factors for Poor Outcome or Death in Young
- 488 Children With Respiratory Syncytial Virus—Associated Acute Lower Respiratory Tract Infection: A
- 489 Systematic Review and Meta-Analysis. J Infect Dis. 2021;226(Supplement\_1):S10-S6.
- 490 https://doi.org/10.1093/infdis/jiaa751.

- 491 31. Deng S, Cong B, Edgoose M, De Wit F, Nair H, Li Y. Risk factors for respiratory syncytial virus-associated
- acute lower respiratory infection in children under 5 years: An updated systematic review and meta-
- 493 analysis. Int J Infect Dis. 2024;146:1-8. <a href="https://doi.org/10.1016/j.ijid.2024.107125">https://doi.org/10.1016/j.ijid.2024.107125</a>.
- 494 32. Pickles RJ, DeVincenzo JP. Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis.
- 495 The Journal of Pathology. 2015;235(2):266-76. https://doi.org/10.1002/path.4462.
- 496 33. Kramer R, Duclos A, Lina B, Casalegno JS. Cost and burden of RSV related hospitalisation from 2012 to
- 497 2017 in the first year of life in Lyon, France. Vaccine. 2018;36(45):6591-3.
- 498 https://doi.org/10.1016/j.vaccine.2018.09.029.
- 499 34. European Medicines Agency (EMA) Science Medicines Health. Synagis Palivizumab. (2023).
- 500 https://www.ema.europa.eu/en/medicines/human/EPAR/synagis. Accessed 2024.
- 501 35. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal
- antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The
- 503 IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531-7.
- 504 36. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for Prevention of
- RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022;386(9):837-46.
- 506 https://doi.org/10.1056/NEJMoa2110275.
- 507 37. Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for Prevention of
- Hospitalizations Due to RSV in Infants. N Engl J Med. 2023;389(26):2425-35.
- 509 https://doi.org/10.1056/NEJMoa2309189.
- 510 38. European Medicines Agency (EMA) Science Medicines Health. Beyfortus Nirsevimab. (2024).
- 511 https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus. Accessed 2024.
- 512 39. Koch J, Berner R, Flasche S, Günther F, Kwetkat A, Lange B, et al. Beschluss und wissenschaftliche
- 513 Begründung zur Empfehlung der STIKO zur spezifischen Prophylaxe von RSV-Erkrankungen mit

- Nirsevimab bei Neugeborenen und Säuglingen in ihrer 1. RSV-Saison. Epid Bull. 2024(26):3-29.
- 515 https://doi.org/10.25646/12198.

- 516 40. Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent Prefusion F Vaccine in
- Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023;388(16):1451-64.
- 518 https://doi.org/10.1056/NEJMoa2216480.
- 519 41. European Medicines Agency (EMA) Science Medicines Health. Abrysvo Respiratory syncytial virus
- vaccine. (2024). <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo">https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo</a>. Accessed 2024.

**Table 1** Number (n) and characteristics of inpatient cases between 2014-2019 in infants and between 2015-2019 in toddlers

-	Infants		Tod	dlers
	1-12 mont	hs	13-24	months
	Incidence	HRU/costs	Incidence	HRU/costs
	cohort,	cohort,	cohort,	cohort,
	n = 5,565	n = 4,909	n = 2,131	n = 1,730
Characteristic	n (%)	n (%)	n (%)	n (%)
Age in months (Mean, ±SD)	5.4 (±3.2)	5.2 (±3.2)	17.9 (±3.3)	17.8 (±3.3)
Sex (female)	2,265 (40.7)	2,033 (41.4)	888 (41.7)	723 (41.8)
Episode type				
RSV	3,522 (63.3)	3,223 (65.7)	679 (31.9)	573 (33.1)
UBP	1,859 (33.4)	1,538 (31.3)	1,390 (65.2)	1,112 (64.3)
RSV+UBP	184 (3.3)	148 (3.0)	62 (2.9)	45 (2.6)
Full term status				
full term	4,825 (86.7)	4,313 (87.9)	1,815 (85.2)	1,505 (87.0)
preterm	670 (12.0)	559 (11.4)	272 (12.8)	208 (12.0)
extreme preterm	70 (1.3)	37 (0.8)	44 (2.1)	17 (1.0)
Risk factors				
any risk factor	1,714 (30.8)	1,430 (29.1)	748 (35.1)	547 (31.6)
no risk factor	3,851 (69.2)	3,479 (70.9)	1,383 (64.9)	1,183 (68.4)
ICU stay				
ICU stay	N/A	43 (0.9)	N/A	12 (0.7)
no ICU stay	N/A	4, 866 (99.1)	N/A	1,718 (99.3)
Ventilatory support				
ventilatory support	N/A	288 (5.9)	N/A	18 (1.0)
no ventilatory support	N/A	4,621 (94.1)	N/A	1,712 (99.0)

**Table 2** Case Numbers (N) and Hospital Incidence Rates (IR) per 1,000 Person-Years per Calendar Year in Children ≤ 2 years of age between 2014-2019

Month of life	2014	2014		2015		2016		2017		2018		2019		2014 - 2019	
	N	IR													
RSV-UBP															
1-3	319	41.69	315	41.71	334	43.30	375	47.45	324	41.55	366	49.66	2,033	44.21	
4-6	290	37.90	262	34.69	288	37.34	275	34.80	240	30.78	271	36.77	1,626	35.36	
7-12	403	26.34	299	19.79	330	21.39	273	17.27	339	21.74	262	17.77	1,906	20.72	
1-6	609	39.80	577	38.20	622	40.32	650	41.13	564	36.16	637	43.21	3,659	39.78	
1-12	1,012	33.07	876	29.00	952	30.86	923	29.20	903	28.95	899	30.49	5,565	30.25	
13-24	NA	NA	399	13.80	521	18.13	323	10.95	463	15.29	425	14.49	2,131	14.52	
1-24	NA	NA	1,275	21.57	1,473	24.72	1,246	20.39	1,366	22.22	1,324	22.51	7,696	23.27	
RSV-specif	ic														
1-3	237	30.98	243	32.17	260	33.71	313	39.61	264	33.86	318	43.14	1,635	35.55	
4-6	174	22.74	169	22.38	204	26.45	214	27.08	158	20.26	213	28.90	1,132	24.62	
7-12	156	10.19	147	9.73	146	9.46	147	9.30	174	11.16	169	11.46	939	10.21	
1-6	411	26.86	412	27.27	464	30.08	527	33.34	422	27.06	531	36.02	2,767	30.08	
1-12	567	18.53	559	18.50	610	19.77	674	21.32	596	19.11	700	23.74	3,706	20.15	
13-24	NA	NA	115	3.98	147	5.12	133	4.51	137	4.53	204	6.95	741	5.05	
1-24	NA	NA	674	11.40	757	12.70	807	13.20	733	11.93	904	15.37	4,447	13.45	

Table 3 Case Numbers (N) and Hospital Incidence Rates (IR) per 1000 per person-years between 2014-2019 stratified by Preterm and Risk Status

	I	nfants		T	oddlers	
	DADB*	N	IR	DADB*	N	IR
RSV-UBP						
No risk	154,769	3,851	24.88	120,892	1,383	11.44
Any risk**	29,183	1,714	58.73	25,860	748	28.92
Underlying disease***	17,756	974	54.85	16,698	432	25.87
Full-term	172,525	4,825	27.97	137,590	1,815	13.19
Any preterm	11,427	740	64.76	9,162	316	34.49
Early/late preterm	10,583	670	63.31	8,530	272	31.89
Extreme preterm	844	70	82.94	632	44	69.62
RSV-specific						
No risk	154,769	2,577	16.65	120,892	459	3.80
Any risk**	29,183	1,129	38.69	25,860	282	10.90
Underlying disease	17,756	646	36.38	16,698	166	9.94
Full-term	172,525	3,223	18.68	137,590	625	4.54
Any preterm	11,427	483	42.27	9,162	116	12.66
Early/late preterm	10,583	451	42.62	8,530	96	11.25
Extreme preterm	844	32	37.91	632	20	31.65

 Note: \* DADB base population, \*\* presence of any risk factor including any underlying disease and prematurity; \*\*\* excluding premature cases

# Table 4 Case Numbers (N), Mean (M) and Standard Deviation (SD) of Direct Costs and Mean Excess Costs

# (in €) in Infants and Toddlers between 2014 – 2019

531

532

			Direct Costs		Excess costs	
	Month	<del>-</del>	Episode	30 days	90 days	365 days
	of life	N	M (SD)	M	M	М
RSV-UBP						
	1-3	1,891	4,738 (11,276)	4,028	4,612	5,065
	4-6	1,430	3,248 (6,183)	3,015	3,349	3,763
	7-12	1,588	3,102 (6,048)	2,975	3,571	4,779
	1-12	4,909	3,775 (8,515)	3,392	3,907	4,593
	13-24	1,730	3,062 (5,859)	3,067	3,484	4,285
RSV-specific						
	1-3	1,536	4,792 (10,809)	4,224	4,692	5,000
	4-6	1,029	3,397 (5,215)	3,180	3,477	3,750
	7-12	806	3,349 (3,850)	3,233	3,838	5,483
	1-12	3,371	4,021 (8,096)	3,669	4,117	4,734
	13-24	618	3,641 (5,804)	3,521	3,921	4,722
UBP						
	1-3	355	4,503 (13,112)	3,176	4,268	5,347
	4-6	401	2,866 (8,153)	2,592	3,019	3,796
	7-12	782	2,847 (7,677)	2,709	3,297	4,053
	1-12	1,538	3,234 (9,348)	2,786	3,449	4,285
	13-24	1,112	2,741 (5,868)	2,815	3,241	4,042

Table 5 Case Numbers (N), Mean (M) and Standard Deviation (SD) of Direct Costs and Mean Excess Costs (in €) by Risk and Preterm Status in Infants and Toddlers (2014 – 2019)

		li li	nfants		Toddlers						
		Direct Costs		Excess costs			Direct Costs		Excess costs		
		Episode	30 days	90 days	395 days		Episode	30 days	90 days	395 day:	
	N	M (SD)	M	M	M	N	M	M	M	M	
RSV-UBP											
No risk	3,479	3,019 (4,136)	2,953	3,129	3,623	1,183	2,822 (4,471)	2,871	3,061	3,3	
Any risk*	1,430	5,613 (14,235)	4,461	5,801	6,953	547	3,583 (8,066)	3,491	4,398	6,2	
Full-term	4,313	3,403 (6,359)	3,287	3,673	4,379	1,505	3,036 (6,105)	3,050	3,435	4,1	
Any preterm	596	6,461 (17,228)	4,151	5,604	6,147	225	3,239 (3,839)	3,180	3,813	5,2	
Early/late preterm	559	5,630 (14,740)	3,982	5,299	6,107	208	3,174 (3,892)	3,111	3,794	5,3	
Extreme preterm	37	19,010 (36,949)	6,694	10,207	6,758	17	4,034 (3,117)	4,034	4,043	4,6	
RSV-specific											
No risk	2,385	3,283 (4,884)	3,183	3,387	3,960	399	3,202 (1,714)	3,198	3,313	3,7	
Any risk*	986	5,806 (12,729)	4,843	5,881	6,606	219	4,441 (9,433)	4,109	5,027	6,4	
Full-term	2,959	3,735 (7,271)	3,581	3,979	4,643	532	3,519 (5,792)	3,415	3,669	4,1	
Any preterm	412	6,073 (12,335)	4,300	5,104	5,385	86	4,398 (5,856)	4,178	5,478	7,9	
Early/late preterm	394	5,357 (9,924)	4,115	4,555	4,976	79	4,279 (5,980)	4,040	5,447	8,0	
Extreme preterm	18	21,750 (33,606)	8,337	17,135	14,320	7	5,743 (4,332)	5,743	5,838	7,5	
UBP											
No risk	1,094	2,442 (1,385)	2,451	2,567	2,889	784	2,628 (5,345)	2,705	2,933	3,1	
Any risk*	444	5,186 (17,120)	3,613	5,622	7,724	328	3,010 (6,963)	3,079	3,978	6,1	
Full-term	1,354	2,678 (3,539)	2,646	3,004	3,800	973	2,772 (6,257)	2,851	3,307	4,1	
Any preterm	184	7,328 (24,944)	3,817	6,723	7,854	139	2,522 (1,203)	2,563	2,782	3,6	
Early/late preterm	165	6,282 (22,419)	3,665	7,078	8,805	129	2,497 (1,220)	2,542	2,781	3,6	
Extreme preterm	19	16,415 (40,611)	5,138	3,644	-406	10	2,838 (948)	2,838	2,787	2,7	

# **Figure 1** Hospital Incidence Rate per cross stratified by months of life and preterm status, risk status 2014-2019

